Drugs / AAVCAGsCD59
AAVCAGsCD59
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03585556 | Sep 2018 → Jan 2020 | wet macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03144999 | Mar → Dec 2017 | dry age related macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04358471 Comparator | Jul 2021 → Jul 2023 | diffuse secondary choroid atrophy, dry age related macular degeneration | Hemera Biosciences | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-01 | Janssen Research & Development, LLC | Results Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting jnj.com ↗
Data from a separate Phase 1 study show all three doses of investigational gene therapy JNJ-1887 met the primary endpoint for safety in adults with geographic atrophy (GA) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-01 | Janssen Research & Development, LLC | Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting jnj.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVCAGsCD59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03585556 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated viral vector serotype 2 (AAVCAGsCD59)” NCT03585556 ↗ |
| Route | Intravitreal | “AAVCAGsCD59 is administered as a single intravitreal injection in an office setting” NCT03144999 ↗ |
| Target | CD59 | “causes normal retinal cells to increase the expression of a soluble form of CD59 (sCD59)” NCT03144999 ↗ |